Skip to main content
. 2021 May;74(5):1064–1074. doi: 10.1016/j.jhep.2020.11.043

Fig. 6.

Fig. 6

HBV core-specific CD8+ T cell responses in patients who achieved HBsAg loss after treatment withdrawal. (A) Representative dot plots of HBV-specific effector CD8+ T cells from 2 patients who lost HBsAg. (B) Longitudinal HBV-specific T cell responses against core OLP in patients that achieved HBsAg loss after stopping therapy. No differences were observed at weeks 12 and 48 when comparing to baseline (Wilcoxon Signed-Rank test).